---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-001905"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:33:55.917110+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Charles River: Q4 DSA book-to-bill ~1.1x; acquires K.F. (Cambodia) for $510M and PathoQuest for ~$60M

## Summary
- Preliminary Q4 DSA net book-to-bill ~1.1x, driven by improved demand from small/mid biotech and global biopharma in Q4.
- 2026 organic revenue guidance expects at least flat growth for consolidated and DSA, with revenue growth returning in H2 2026.
- Non-GAAP operating margin outlook includes >$100M in incremental cost savings to offset inflation until revenue growth resumes.
- Acquiring K.F. (Cambodia) for ~$510M; accretive $0.25 in 2026, $0.60 in 2027; close expected early Q1 2026.
- Exercising option to buy remaining 79% of PathoQuest for ~€51.6M (~$60M); close by end Q1 2026, not material to 2026/2027 results.

## SEC filing metadata
- accession: 0001628280-26-001905
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000162828026001905/0001628280-26-001905-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000162828026001905/crl-20260113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-001905
- JSON: https://secwatch.observer/filing/0001628280-26-001905.json
- Plain text: https://secwatch.observer/filing/0001628280-26-001905.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.